ReviewBiomedicines2023
Glutathione: Lights and Shadows in Cancer Patients.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Genome-wide association study and Mendelian randomization analyses reveal insights into bladder cancer etiology.JNCI cancer spectrum · 2025Pooled it
- Tumor Microenvironment-Responsive Polymeric Nanocarriers for the Treatment of Triple-Negative Breast Cancer.Pharmaceutics · 2026Review
- Disulfidptosis and its molecular mechanisms in cancer: mechanisms, regulation, and therapeutic potential.Medical oncology (Northwood, London, England) · 2026Review
- Glutathione in Our Diet and Its Role in the Body: From Disease Prevention to Anti-Aging.Nutrients · 2026Review
- Whey Processed Oxymel induces apoptosis and S-phase arrest in MCF7 and MDA-MB-468 breast cancer cells.Scientific reports · 2026Article
- Glutamate-cysteine ligase catalytic related glutathione metabolism inhibited high mobility group box 1 release by regulating epithelium ferroptosis in asthma.Journal of thoracic disease · 2026Article
- Dual-action mitochondria-targeted prodrugs that both deplete mitochondrial glutathione and deliver a toxic payload to the matrix.European journal of medicinal chemistry · 2026Article
- Glutathione Redox Activity-An Adaptative Mechanism in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2026Article
- Therapeutic Potential of Cysteine and Its Derivatives in Dermatology.Molecules (Basel, Switzerland) · 2026Review
- GSH and CES2 dual-responsive biosensor for dual-signal electron spin resonance (ESR) sensing and free radical-enhanced triple-mode therapy of hepatocellular carcinoma.Analytical and bioanalytical chemistry · 2026Article
- Redox Signaling Disruption and Antioxidants in Toxicology: From Precision Therapy to Potential Hazards.Cell biochemistry and biophysics · 2025Review
- Cancer-Related Malnutrition and Oxidative Stress in Colorectal Cancer Surgery: A Narrative Review of Pathophysiology and Postoperative Outcomes.Antioxidants (Basel, Switzerland) · 2025Review
- Safranal Alleviates Cyclophosphamide Induced Testicular Toxicity in Rats.Food science & nutrition · 2025Article
- Influence of Vitamin D and Its Analogues in Type-B Lymphomas.Current oncology (Toronto, Ont.) · 2025Review
- In vitro anticancer, antioxidant and chelating activities of natural organosulfur compounds originated from Türkiye: an investigation on breast and colorectal cancer cells.Turkish journal of medical sciences · 2025Article
- Identification of disulfidptosis in esophageal squamous cell carcinoma based on single-cell and bulk RNA-seq data to predict prognosis and treatment response.Frontiers in immunology · 2025Article
- A prognostic signature of Glutathione metabolism-associated long non-coding RNAs for lung adenocarcinoma with immune microenvironment insights.Frontiers in immunology · 2025Article
- Disulfidptosis: a novel cell death modality induced by actin cytoskeleton collapse and a promising target for cancer therapeutics.Cell communication and signaling : CCS · 2024Review
- Review
- Design and In Vitro Activity of Furcellaran/Chitosan Multilayer Microcapsules for the Delivery of Glutathione and Empty Model Multilayer Microcapsules Based on Polysaccharides.Materials (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In cases of cellular injury, there is an observed increase in the production of reactive oxygen species (ROS). When this production becomes excessive, it can result in various conditions, including cancerogenesis. Glutathione (GSH), the most abundant thiol-containing antioxidant, is fundamental to re-establishing redox homeostasis. In order to evaluate the role of GSH and its antioxi-dant effects in patients affected by cancer, we performed a thorough search on Medline and EMBASE databases for relevant clinical and/or preclinical studies, with particular regard to diet, toxicities, and pharmacological processes. The conjugation of GSH with xenobiotics, including anti-cancer drugs, can result in either of two effects: xenobiotics may lose their harmful effects, or GSH conjugation may enhance their toxicity by inducing bioactivation. While being an interesting weapon against chemotherapy-induced toxicities, GSH may also have a potential protective role for cancer cells. New studies are necessary to better explain the relationship between GSH and cancer. Although self-prescribed glutathione (GSH) implementation is prevalent among cancer patients with the intention of reducing the toxic effects of anticancer treatments and potentially preventing damage to normal tissues, this belief lacks substantial scientific evidence for its efficacy in reducing toxicity, except in the case of cisplatin-related neurotoxicity. Therefore, the use of GSH should only be considered under medical supervision, taking into account the appropriate timing and setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.